-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The replacement product of Tektronix's blockbuster drug Rituxan also targets CD20.
As we all know, the core patent of Roche's blockbuster product Rituximab (rituximab) has expired.
From the Insight database (http://db.
The domestic research and development of rituximab seems to have entered the Red Sea.
Rituximab domestic competition landscape
From the Insight database (http://db.
Roche's rituximab is under the enemy, and the approval of otuzumab will enable it to be introduced to the domestic market when domestic rituximab is intensively approved, ensuring Roche's position in the CD20 field in China.
The Insight database shows that Roche's otuzumab was reported to market in September 2019 and was included in the priority review and approval in December of the same year.
From the Insight database (http://db.
On September 18, 2019, based on the excellent data of phase II clinical NOBILITY, the FDA granted its CD20 antibody Gazyva breakthrough therapy designation for the treatment of adult lupus nephritis.
Note: The original text has been deleted
